HBSAg anticorps

N° du produit ABIN731303

Détail du produit anti-HBSAg anticorps

Antigène: HBSAg (HBsAg) (Hepatitis B Virus Surface Antigen (HBsAg))

Reactivité: Virus, Humain, Souris

Hôte: Chèvre

Clonalité: Polyclonal

Conjugué: Cet anticorp HBSAg est non-conjugé

Application: ELISA, Western Blotting (WB), Immunofluorescence (Paraffin-embedded Sections) (IF (p)), Immunofluorescence (Cultured Cells) (IF (cc)), Immunohistochemistry (Frozen Sections) (IHC (fro)), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Réactivité croisée: Humain, Souris, Virus

Homologie: Bee

Purification: Purified by Protein A.

Immunogène: Human Hepatitis B Surface Antigen

Isotype: IgG

Information d'application

Indications d'application: WB 1:300-5000
ELISA 1:500-1000
IHC-P 1:200-400
IHC-F 1:100-500
IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 1 μg/μL

Buffer: Aqueous buffered solution containing 0.01M TBS ( pH 7.4) with 1 % BSA, 0.02 % Proclin300 and 50 % Glycerol.

Agent conservateur: ProClin

Précaution d'utilisation: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.

Stock: -20 °C

Stockage commentaire: Store at -20°C for 12 months.

Date de péremption: 12 months

Références pour anticorps anti-HBSAg (ABIN731303)

Andriamandimby, Olive, Shimakawa, Rakotomanana, Razanajatovo, Andrianinarivomanana, Ravalohery, Andriamamonjy, Rogier, Héraud: "Prevalence of chronic hepatitis B virus infection and infrastructure for its diagnosis in Madagascar: implication for the WHO's elimination strategy." dans: BMC public health, Vol. 17, Issue 1, pp. 636, (2018) (PubMed).

Sakurai, Mitani, Yamamoto, Takayama, Tachibana, Watashi, Wakita, Iijima, Tanaka, Mizuguchi: "Human induced-pluripotent stem cell-derived hepatocyte-like cells as an in vitro model of human hepatitis B virus infection." dans: Scientific reports, Vol. 7, pp. 45698, (2017) (PubMed).

Nakabori, Hikita, Murai, Nozaki, Kai, Makino, Saito, Tanaka, Wada, Eguchi, Takahashi, Suemizu, Sakamori, Hiramatsu, Tatsumi, Takehara: "Sodium taurocholate cotransporting polypeptide inhibition efficiently blocks hepatitis B virus spread in mice with a humanized liver." dans: Scientific reports, Vol. 6, pp. 27782, (2016) (PubMed).

Ito, Ando, Nakamura, Ishida, Kanbe, Kobiyama, Yamamoto, Ishii, Hara, Seishima, Ishikawa: "Induction of humoral and cellular immune response to hepatitis B virus (HBV) vaccine can be upregulated by CpG oligonucleotides complexed with Dectin-1 ligand." dans: Journal of viral hepatitis, (2016) (PubMed).

Yu, Wang, Tian, Wang, Li, Yuan, Chen, Li, Zhuang, Ling: "Comparison of the patterns of antibody recall responses to HIV-1 gp120 and hepatitis B surface antigen in immunized mice." dans: Vaccine, Vol. 34, Issue 50, pp. 6276-6284, (2016) (PubMed).

Lai, Liang, Lin, Huang, Huang, Chen, Yeh: "Hepatocarcinogenesis in transgenic mice carrying hepatitis B virus pre-S/S gene with the sW172* mutation." dans: Oncogenesis, Vol. 5, Issue 12, pp. e273, (2016) (PubMed).

Watanabe, Hamada-Tsutsumi, Yokomaku, Imamura, Sugiura, Tanaka: "Postexposure Prophylactic Effect of Hepatitis B Virus (HBV)-Active Antiretroviral Therapy against HBV Infection." dans: Antimicrobial agents and chemotherapy, Vol. 59, Issue 2, pp. 1292-8, (2015) (PubMed).

Okumura, Ikeda, Satoh, Dansako, Sugiyama, Mizokami, Kato: "Negative regulation of hepatitis B virus replication by forkhead box protein A in human hepatoma cells." dans: FEBS letters, Vol. 589, Issue 10, pp. 1112-8, (2015) (PubMed).

Ma, Song, Teng, Fu, Hao, Chen, Xu, Gu: "Successful establishment and evaluation of a new animal model for studying the hepatitis B virus YVDD mutant." dans: Archives of virology, Vol. 158, Issue 4, pp. 785-91, (2013) (PubMed).

Xiang, Wei, Lei, Liu, Liu, Guo: "A simple and rapid capillary chemiluminescence immunoassay for quantitatively detecting human serum HBsAg." dans: European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, Vol. 32, Issue 12, pp. 1557-64, (2013) (PubMed).

Gong, Liu, Dong, Zhou, Li et al.: "Construction and expression of a recombinant eukaryotic expression plasmid containing the preS1-preS2-S genes of hepatitis B virus and the granulocyte-macrophage colony stimulating factor gene: A ..." dans: Biomedical reports, Vol. 1, Issue 2, pp. 251-256, (2013) (PubMed).

Détails sur HBSAg

Antigène: HBSAg (HBsAg) (Hepatitis B Virus Surface Antigen (HBsAg))

Autre désignation: HBsAg (HBsAg Produits)

Classe de substances: Viral Protein

Sujet:

Synonyms: HBsAg, HBV major surface antigen, HBV surface antigen, Hepatitis B Virus major surface antigen, Major surface antigen, S, Human Hepatitis B Surface Antigen

Background: Hepatitis B Virus (HBV) infection induces a disease state characterised by liver damage, inflammation and viral persistence. Infection also increases the risk of hepatocellular carcinoma. HBV belongs to the Hepadnaviridae family of viruses. Its genome consists of partially double stranded circular DNA. The DNA is enclosed in a nucleocapsid, or core antigen (HBcAg), which is surrounded by a spherical envelope (surface antigen or HBsAg). The core antigen shares its sequences with the e antigen (HBeAg) but no cross reactivity between the two proteins has been observed. The HBV genome also encodes a DNA polymerase that also acts as a reverse transcriptase. Hepatitis B infection is normally diagnosed from serological tests that detect HBsAg but as the disease progresses this antigen may no longer be present in the blood and tests for HBcAg are used. If HBsAg can be detected in the blood for longer than six months, chronic hepatitis B is diagnosed. The antigenic determinant of the protein moiety of the HBsAg determines specific characteristics of different serotypes and provides the basis of immunodetection. HBsAg has antigenic heterogeneity, specifically, two pairs of sub specific determinants, d/y and w/r allow the following combinations: adw, ayw, adr, ayr.

UniProt: Q67926